IMMUNOCORE HOLDINGS PL

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

14 Sep 2024 02:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 2024 Cantor Global Healthcare Conference

12 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Immunocore announces transition of Chief Financial Officer

29 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore reports second quarter financial results and provides a business update

08 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

01 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

18 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

01 Jun 2024 06:59:59 By Nasdaq GlobeNewswire

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

31 May 2024 15:05:00 By Nasdaq GlobeNewswire

Immunocore to present at the Jefferies Global Healthcare Conference

30 May 2024 15:00:00 By Nasdaq GlobeNewswire

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

29 May 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore reports first quarter financial results and provides a business update

08 May 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore announces upcoming presentation and posters at ASCO 2024

24 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

04 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Immunocore presented two posters at CROI 2024

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

01 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

28 Feb 2024 06:34:03 By Nasdaq GlobeNewswire

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

22 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

21 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Immunocore Prices Upsized Convertible Senior Notes Offering

30 Jan 2024 22:30:00 By Nasdaq GlobeNewswire

Immunocore Announces Proposed Convertible Senior Notes Offering

29 Jan 2024 15:05:00 By Nasdaq GlobeNewswire